Glassy Carbon Electrode-Integrated Microfluidic CD Platform for Point-of-Care Detection of SARS-CoV-2 Spike Protein and Prostate-Specific Antigen

In the modern world of medicine, the ability to diagnose illness quickly and accurately outside of a hospital is a critical goal. For decades, doctors have relied on large, stationary machines to analyze blood samples, a process that often requires sending specimens to a central laboratory and waiting days for results. This delay can be dangerous when time is of the essence, such as during a viral outbreak or when monitoring a slow-growing disease. To solve this, scientists have turned to microfluidics, a field dedicated to manipulating tiny amounts of fluid on a small chip. Imagine a laboratory shrunk down to the size of a coin, where pumps, mixers, and sensors are built directly into the surface. When combined with a spinning motion, similar to how a record player works, these chips can use centrifugal force to separate blood components without needing any external tubes or electric pumps. This approach, known as a "lab-on-a-disc," promises to bring the power of a full laboratory to a doctor's office or a remote village, provided the sensors inside are sensitive enough to detect the faint signals of disease.

Building on this concept, researchers Naresh Mandal and Bidhan Pramanick have developed a new diagnostic tool that merges this spinning microfluidic technology with a highly sensitive type of electrical sensor. Their work, detailed in a recent study, focuses on creating a device capable of detecting two very different health threats at the same time: the spike protein of the SARS-CoV-2 virus, which causes COVID-19, and prostate-specific antigen, a marker for prostate cancer. The core of their invention is a tiny electrode made from glassy carbon, a material known for its stability and ability to conduct electricity efficiently. Unlike traditional sensors that might require complex chemical labels to glow or change color, this device works by measuring how easily electricity flows across its surface. When a specific disease marker binds to the sensor, it acts like a tiny barrier, slowing down the electrical current. By measuring this change, the device can identify the presence of the virus or the cancer marker with extreme precision.

The researchers constructed these sensors using a process that involves burning a special plastic film in a controlled, oxygen-free environment. This technique, called pyrolysis, transforms the plastic into a solid, glass-like carbon structure with a microscopic texture that is perfect for catching disease markers. They then coated these carbon surfaces with antibodies, which are proteins designed to act like molecular magnets, sticking only to the specific target they are looking for. For one set of sensors, they used antibodies that bind to the SARS-CoV-2 spike protein; for another, they used antibodies that bind to prostate-specific antigen. To ensure the device works reliably, they also added a layer of bovine serum albumin, a common protein used to block any sticky spots on the sensor that might catch the wrong things, ensuring that only the intended targets are detected.

The true innovation lies in how these sensors are integrated into a spinning disc made of clear plastic. The team designed a microfluidic channel system that allows a drop of whole blood to be placed on the disc. As the disc spins, the centrifugal force pushes the heavier red blood cells to the outer edge, while the lighter plasma, which contains the disease markers, stays closer to the center. This separation happens automatically, without any human intervention or external pumps. The separated plasma then flows over the glassy carbon sensors embedded in the disc. Because the sensors are so sensitive, they can detect the SARS-CoV-2 spike protein at concentrations as low as 0.9844 fg/mL and prostate-specific antigen at 0.9682 pg/mL. These numbers represent incredibly small amounts, far below what many standard tests can see, allowing for the detection of diseases at very early stages.

The study demonstrates that this system can measure the electrical response of the sensors as the blood plasma flows over them, providing a clear signal when the target proteins are present. The researchers tested the device across a wide range of concentrations, from the tiniest trace amounts up to much higher levels, and found that the response was consistent and linear. This means the device does not just detect the presence of a marker; it can also quantify how much is there, which is vital for monitoring the progression of an infection or a cancer. The entire setup is self-contained, requiring no external power sources for the fluid movement, making it an ideal candidate for point-of-care use in places where electricity or advanced laboratory equipment is scarce.

While the current work focuses on the fabrication and testing of the device with prepared samples, the results suggest a powerful path forward for decentralized healthcare. The combination of a robust carbon sensor and a simple, spinning disc creates a platform that is low-cost, portable, and capable of handling multiple tests at once. The researchers note that the next steps will involve testing the device with real patient blood samples to confirm its performance in a clinical setting. By proving that such a sensitive, dual-purpose detector can be built and operated on a small disc, this work offers a tangible solution for bringing advanced diagnostic capabilities to the most remote and resource-limited areas of the world.